Changeflow GovPing Telecom & Technology Deep learning-based prediction for monitoring o...
Routine Notice Added Final

Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy

Favicon for changeflow.com ChangeBridge: EPO Bulletin - AI & Computing (G06N)
Published
Detected
Email

Summary

European Patent Office published Amgen's patent EP4423483A1 for deep learning algorithms applied to spectroscopic data analysis for pharmaceutical monitoring and quality control. The invention covers neural network-based prediction methods for analyzing spectroscopic signals in drug manufacturing. Designated states include all major European markets (DE, FR, GB, IT, ES, NL, BE, etc.).

What changed

The European Patent Office published patent EP4423483A1 for Amgen Inc., covering deep learning methods for predicting pharmaceutical characteristics from spectroscopic data. The invention applies neural networks to analyze spectral signals for real-time monitoring and quality control in drug manufacturing processes.

Pharmaceutical manufacturers using spectroscopic monitoring with AI components should review this patent for potential licensing implications or freedom-to-operate considerations. Technology companies developing AI-based pharmaceutical analysis tools may also need to assess design-around options to avoid infringement in designated European states.

What to do next

  1. Monitor for updates on patent portfolio implications

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

DEEP LEARNING-BASED PREDICTION FOR MONITORING OF PHARMACEUTICALS USING SPECTROSCOPY

Publication EP4423483A1 Kind: A1 Apr 01, 2026

Applicants

Amgen Inc.

Inventors

KHODABANDEHLOU, Hamid, WANG, Tony, Y., TULSYAN, Aditya, SCHORNER, Gregory, L.

IPC Classifications

G01N 21/359 20140101AFI20230505BHEP G01N 21/65 20060101ALI20230505BHEP G01J 3/00 20060101ALI20230505BHEP G01J 3/02 20060101ALI20230505BHEP G01J 3/08 20060101ALI20230505BHEP G01N 30/02 20060101ALI20230505BHEP G06N 3/08 20230101ALI20230505BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for ChangeBridge: EPO Bulletin - AI & Computing (G06N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4423483A1

Who this affects

Applies to
Pharmaceutical companies Technology companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant AI-based monitoring Spectroscopic analysis
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Artificial Intelligence Pharmaceuticals Data Privacy

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - AI & Computing (G06N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.